What Is 5-Amino-1MQ and How Does It Work
5-Amino-1MQ is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme expressed at elevated levels in white adipose tissue. Worth noting up front: 5-Amino-1MQ is not a peptide - it's a methylquinolinium small molecule - though it is commonly marketed and sold alongside peptides in the research chemical space, which is why it shows up in peptide-focused catalogs and guides.
NNMT normally diverts nicotinamide away from the NAD+ salvage pathway, converting it to 1-methylnicotinamide (1-MNA) via a reaction that consumes S-adenosylmethionine (SAM). By competitively inhibiting NNMT, 5-Amino-1MQ is studied for its ability to keep more nicotinamide available for recycling into NAD+ through NAMPT, while preserving intracellular SAM. In adipocyte and mouse models, this shift has been associated with suppressed lipogenesis, reduced adipocyte size, and lower body weight - a proposed mechanism for reducing fat cell growth and supporting metabolic rate that does not rely on stimulant activity.
Research Dosing
There is no clinically validated human dosing protocol for 5-Amino-1MQ. The figures below combine what the foundational animal research used with what is commonly cited in research-community protocols - these are not equivalent sources, and neither constitutes medical guidance.
| Source | Dose | Frequency | Route |
|---|---|---|---|
| Foundational mouse study | 20mg/kg | 3× daily, 11 days | SubQ injection (animal model) |
| Commonly cited research-community range | ~50–150mg/day (hedged - not a validated clinical dose) | 1–2× daily, 8–12 week cycles | Oral capsule |
Context: The 20mg/kg subcutaneous mouse dose does not translate directly to a human oral equivalent. The 50-150mg/day oral range circulating in research-community protocols is a convention drawn from vendor and community sources rather than a published, peer-reviewed human dosing trial - treat it as a loosely established starting reference, not a validated figure.
Regulatory Status
5-Amino-1MQ has not been evaluated or approved by the FDA for any human indication, and it is not currently listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as "5-Amino-1MQ" - including the one carried in the BioStackIQ shop - are marketed and sold as research chemicals for laboratory and research use only, not for human consumption. This is a legal distinction, not a safety endorsement: research-use framing does not indicate that a product has been evaluated by any regulator for human safety or efficacy. Consult a qualified healthcare provider before considering any research compound protocol.
What Research Shows
The evidence base for 5-Amino-1MQ is preclinical. The compound was developed and characterized as a selective, membrane-permeable NNMT inhibitor and tested in diet-induced obese mice, where it reduced body weight and white adipose mass, lowered plasma cholesterol, and decreased adipocyte size without changing food intake - alongside supporting in vitro adipocyte data showing increased NAD+ and SAM and suppressed lipogenesis. No completed human clinical trials of 5-Amino-1MQ have been published, so claims about human fat loss or metabolic-rate effects remain extrapolations from animal and cell-culture data rather than confirmed human outcomes.
For a broader look at how metabolic-support compounds are sequenced alongside other research peptides, see the peptide stack beginner's guide.